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Abstract
Introduction. The initial clinical experience from targeted therapy for breast cancer has been mixed. While important
progress has been made in the care of a subset of patients characterized by ampliﬁcation of HER2 through the use of
trastuzumab, other targeted therapies have failed to improve the outcome for large, unselected groups of patients. Thus, efforts
to ﬁnd prognostic or predictive biomarkers to enable tailored therapy are highly warranted. Genetically engineered mouse
models of human cancer provide a convenient setting in which to perform explorative studies. However, there is a paucity of
comparative studies between mouse and human tumours in order to validate the use of mouse models as discovery tools.
Materials and methods. Here, we have compared the localization of markers for cancer-associated ﬁbroblasts in the
MMTV-PyMT mouse model of mammary carcinoma with that of human breast cancer. The expression of a-smooth muscle
actin, platelet-derived growth factor receptor-a, and ﬁbroblast-speciﬁc protein-1 was assessed by immunostaining of sections
from tumours of MMTV-PyMT mice. Information about the distribution of the same markers in human breast cancer was
derived from the publicly available database the Human Protein Atlas.
Results. Both mouse and human mammary carcinomas were infused by a rich ﬁbrotic stroma. While no marker was capable of
identifying all stromal ﬁbroblasts, the expression pattern of each marker was remarkably similar in mouse and human.
Discussion. We conclude that the MMTV-PyMT mouse model of breast cancer will have utility as a discovery tool for
biomarkers of cancer-associated ﬁbroblasts during malignant conversion.
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Introduction
The recent development of targeted therapy for can-
cer has been introduced into clinical practice over the
course of the past decade. High hopes were placed on
targeting speciﬁc over-active signalling pathways
within tumours following the preceding successful
drug development in the preclinical setting. Indeed,
the therapeutic efﬁcacy observed in mouse models of
cancer has been translated into clinical beneﬁt for
patients. As a case in point, the humanized antibody
trastuzumab (Herceptin), targeting the receptor tyro-
sine kinase HER2 in breast cancer, improves disease-
free survival in HER2
+ patients by 52% when
administered in the adjuvant setting and prolongs
overall survival by 24% for patients with metastatic
disease (1,2). Nevertheless, many targeted therapies
have failed to provide substantial improvement in
survival in large phase III clinical trials. The main
reason for this shortfall is a lack of reliable biomarkers
predictive of response to therapy. In the few cases
where robust biomarkers have been identiﬁed, such as
HER2 ampliﬁcation for trastuzumab treatment of
breast cancer and lack of K-ras mutations for erlotinib
treatment of non-small cell lung cancer (3,4), patient
subsets that beneﬁt signiﬁcantly can be readily
distinguished. In order to facilitate the discovery
and genome-wide analysis of biomarkers for different
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progression, the use of disease-speciﬁc genetically
engineered mouse models of cancer with proven
translational capacity will be increasingly valuable.
Thus, there is a growing need for comparative studies
between human and mouse tumours in order to
validate preclinical models as surrogates for explor-
ative studies aimed at ﬁnding new biomarkers
and/or targets for cancer therapy.
Tumours are communicating organs. During the
course of malignant conversion, cancer cells engage
multiple different neighbouring cell types in the
stroma; paracrine signalling between endothelial cells,
pericytes, cancer-associated ﬁbroblasts (CAFs),
immune cells, thrombocytes, and the extracellular
matrix provides a setting in which the tumour and
stroma compartments co-evolve into a clinically
manifested disease (5,6). As a rich provider of factors
that collectively sustain tumour cell proliferation,
survival, invasion, metastatic dissemination, and
angiogenesis, the tumour stroma is currently an
underestimated source of therapeutic targets and
biomarkers with prognostic and predictive potential.
We set out to validate the use of a genetically
engineered mouse model of breast cancer in the
discovery of new biomarkers and therapeutic targets
derived from CAFs. Pre-malignant lesions from
MMTV-PyMT mice were found to be infused with
CAFs already at an early stage. In overt invasive
carcinomas, the marker-speciﬁc distribution and
abundance of CAFs were remarkably similar to that
of the human counterpart. Thus, we conclude that the
MMTV-PyMT mouse model of breast cancer may
have utility as a discovery tool for studies of CAFs
during the malignant conversion of mammary
carcinomas.
Material and methods
Mice and tumour samples
FVB/N-Tg(MMTV-PyVT)
634Mul/J transgenic mice
have been described previously (7) and were pur-
chased from the Jackson Laboratory. Mice of differ-
ent ages (6,11, and 14 weeks) were anaesthetized
with Avertin (Sigma Aldrich, St Louis, MO) and
then euthanized by heart perfusion with Hanks’
balanced salt solution followed by 4% paraformal-
dehyde (PFA). The left cervical and thoracic
mammary glands were excised and subjected to over-
night ﬁxation in 4% PFA before embedding in par-
afﬁn. All animal experiments were approved by
the Ethical Committee for Animal Experiments
(Stockholm Norra djurförsöksetiska nämnd, appli-
cation N96/11).
Immunohistochemical analysis
Parafﬁn-embedded mouse mammary tissues were
sectioned in 5 mm and adhered to glass slides, depar-
afﬁnized, and boiled in EnVision
  FLEX Target
Retrieval Solution (DAKO, Glostrup, Denmark)
for 20 min. Slides were incubated in 10% goat
serum in TNBblocking solution (Perkin-Elmer Life
Sciences, Waltham, MA). Antibodies were diluted in
blocking buffer and incubated overnight; mouse
anti-a-SMA (C-6198, Sigma Aldrich, St Louis,
MO), rabbit anti-PDGFRa (#3164, Cell Signalling
Technology, Danvers, MA), and rabbit anti-FSP1
(a kind gift from Dr Eric Neilson, Vanderbilt
University, TN). After 1-h incubation with biotiny-
lated secondary antibodies in blocking solution, the
slides were subjected to an ampliﬁcation step using
Vectastain ABC kit (PK-6100 Standard, Vector
Laboratories, Burlingame, CA). Peroxidase Substrate
Kit DAB (Vector Laboratories) was used to develop
and visualize the stainings. Slides were counterstained
with Harris hematoxylin, dehydrated and mounted
using X-TRA KITT (Medite Medizintechnik,
Burgdorf, Germany). Images were taken using a Zeiss
Observer Z1 microscope and an AxioCam HRc
Zeiss camera.
Results
The MMTV-PyMT mouse is a prototypical geneti-
cally engineered mouse model for multistage develop-
ment of invasive ductal carcinoma of the breast (7).
Tumours from MMTV-PyMT mice have previously
been thoroughly characterized both genetically and
histologically in terms of the tumour cell compart-
ment compared to the human counterpart (8-10).
However, as of yet, no comprehensive evaluation of
the marker expression of CAFs has been reported. We
have compared the expression and distribution
of three widely used markers for CAFs and
myoﬁbroblasts—a-smooth muscle actin (ASMA),
platelet-derived growth factor receptor-a (PDGFRa),
and ﬁbroblast-speciﬁc protein-1 (FSP1)—in tumours
from MMTV-PyMT mice of different ages and
human breast cancers. At 6 weeks of age, MMTV-
PyMT mice present with small hyperplastic lesions or
mammary intra-epithelial neoplasias (Figure 1).
Immunostaining for ASMA, PDGFRa, and FSP1
revealed that each of the CAF markers is expressed
by spindle-shaped stromal cells inﬁltrating into the
mass of epithelial cells already at this early stage of
tumour development (Figure 1A–C). None of the
markers identiﬁed all stromal ﬁbroblasts, indicating
that there are different subsets of CAFs recruited into
tumours (Figure 1A–C). Notably, ASMA was also
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some of the tumour cell nests, as expected (data
not shown).
Next, we analysed the abundance and marker
proﬁle of CAFs harboured within tumours from
11- and 14-week-old MMTV-PyMT mice. No major
differences were noted in the expression pattern of
ASMA, PDGFRa, or FSP1 between early and late
tumours, even though the areas of ﬁbroblast-
rich stroma increased in size over tumour progression
(data not shown). At 14 weeks of age, MMTV-
PyMT mice presented with overt carcinomas infused
with a ﬁbroblast-rich stroma (Figure 2). Again, there
was no marker capable of identifying all CAFs. Immu-
nostaining for ASMA and PDGFRa yielded a similar
pattern, with positive cells being predominantly elon-
gated and located within streaks bridging nests of
tumour cells (Figure 2A, B). In contrast, while still
being located within ﬁbrotic streaks surrounding
tumour cell clusters, most FSP1
+ cells were found
to be rounded in shape (Figure 2C). In addition, a
fraction of the cells expressing FSP1 was also inter-
spersed as single cells between epithelial cells
(Figure 2C).
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Figure 2. Expression of ﬁbroblast markers in 14-week-old MMTV-PyMT mice. Representative immunostaining of tumour tissue from a
14-week-old MMTV-PyMT mouse showing the expression pattern of ASMA (A), PDGFRa (B), and FSP1 (C). The staining pattern for
ASMA and PDGFRa shows similar staining pattern where staining of spindle-shaped stromal cells could be seen. For FSP1 not only stromal
streaks were stained but also some cells intermingled in the epithelial islets. Scale bar is indicated in the ﬁgure and represents 50 mm.
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Figure 1. Expression of ﬁbroblast markers in 6-week-old MMTV-PyMT mice. Representative immunostaining of hyperplastic lesions of a
6-week-old MMTV-PyMT mouse showing the expression pattern of ASMA (A), PDGFRa (B), and FSP1 (C). Scale bar is indicated in the
ﬁgure and represents 50 mm.
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expression in tumours from MMTV-PyMT mice and
human breast cancer, we analysed the abundance
and phenotype of cells marked by ASMA, PDGFRa,
and FSP1 using publicly available data from the
Human Protein Resource (see: http://www.proteina-
tlas.org) (11). The expression of each CAF marker in
human tumours was heterogenous and varied from
patient to patient. Nevertheless, the consensus stain-
ing pattern for ASMA, PDGFRa, and FSP1 was
remarkably similar to that of the tumours from
MMTV-PyMT mice (Figure 3A–C). Thus, cells
expressing ASMA and PDGFRa were located in
ﬁbrotic streaks and displayed a spindle-shaped mor-
phology (Figure 3A, B), whereas FSP1
+ cells were
distinguished by a rounded shape and located both in
the overt stroma and within tumour cell clusters
(Figure 3C).
In summary, none of the markers used in this study
was able to identify all subsets of CAFs. However,
striking similarities between mouse and human breast
tumours were found in terms of the distribution and
morphology of stromal ﬁbroblasts expressing ASMA,
PDGFRa, and FSP1, respectively.
Discussion
Previous comparisons between tumours from
genetically engineered mouse models and human
breast cancer have mainly focused on the tumour
cells (12). Lesions from the initial stages of
malignant transformation of the MMTV-PyMT
mouse have been found mostly to resemble human
breast cancers of the luminal B subgroup with
expression of ER/PR and HER2 as common
denominators (9). With increasing malignancy,
mouse tumours tend to lose expression of hormone
receptors, while HER2 expression escalates. Indeed,
tumour shrinkage can be readily induced in
M M T V - P y M Tm i c eb yt r e a t ment with trastuzumab
(K.P., unpublished observation). Evaluations of the
human resemblance of the stromal compartment of
tumours from the MMTV-PyMT mouse are scarce,
even though it was noted in a pathologist consensus
report on mouse models of mammary carcinoma
that these tumours harbour a densely sclerotic
stroma (12). Here, we have contrasted the localiza-
tion and abundance of three different markers for
CAFs in tumours from MMTV-PyMT mice with
human breast cancer. As noted in previous studies
(13-15), no marker labelled all stromal ﬁbroblasts,
suggesting that different subsets of CAFs populate
the tumour stroma already at an early stage. While it
is unclear whether different subtypes of CAFs rep-
resent different functionalities, various subsets may
also reﬂect different origins, since CAFs have been
reported to be recruited into tumours from both
local and remote sources (14,16). Of note, tumours
from the MMTV-PyMT mouse model faithfully
reproduced the staining pattern of the CAF markers
ASMA, PDGFRa, and FSP1 found in human
tumours. Thus, the close similarity between mouse
ASMA
Human
Mouse
PDGFRα FSPI
ASMA PDGFRα FSPI
ABC
Figure 3. Correlation between CAF markers in mouse and human breast cancer. Immunostainings for ASMA (A), PDGFRa (B), and
FSP1 (C), show a similar expression pattern in human (upper panel) and mouse (lower panel) mammary tumour tissue. Scale bar is indicated
in the ﬁgure and represents 50 mm.
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notion of using genetically engineered mice in the
discovery process of CAF-derived therapeutic tar-
gets and biomarkers.
The pursuit of predictive biomarkers will be impe-
rative to enable tailored targeted therapy to patients.
However, the search for such markers should not be
conﬁned to the tumour cell compartment. The
pre-malignant epithelium and surrounding stromal
compartment continuously fertilize each other during
the malignant conversion. Thus, molecular changes
indicative of prognosis and/or therapeutic response
may arise early during tumour progression. Indeed, it
may even be that the metastatic microenvironment is
shaped already before tumour cells are present,
thereby raising the possibility that changes manifested
in the stroma of would-be metastatic organs can serve
as useful markers for preventive measures (17). We
found that stromal ﬁbroblasts expressing ASMA,
PDGFRa, and FSP1 readily inﬁltrate early pre-
malignant lesions from MMTV-PyMT mice, again
indicating that CAFs are particularly interesting tar-
gets for the discovery of biomarkers also for early
stages of the disease.
Genome-wide efforts have recently identiﬁed
stromal gene expression signatures with prognostic
or predictive capabilities in breast cancer (18,19).
Finak et al. identiﬁed a 26-gene stroma-derived
signature that distinguished between good, poor,
and mixed survival in three independent data sets
of more than 750 breast cancer patients (19). Like-
wise, a second gene signature from the tumour
stroma was found to hold predictive power for the
outcome of neoadjuvant chemotherapy in breast
cancer (18). These studies provide proof of principle
that the stromal compartment of tumours inﬂuences
the prognosis and outcome of the disease. However,
the breast tumour microenvironment contains a
m i x e dp o p u l a t i o no fc e l l s ,i n c l u d i n gﬁbroblasts,
endothelial cells, pericytes, immune cells, and adi-
pocytes, and information may thereby be diluted
when considering the total gene expression proﬁle
of the stroma. Thus, efforts to fractionate tumours
into different cellular compartments and analyse the
undiluted and isolated cell types for prognostic or
predictive biomarkers may hold greater utility. The
use of CAFs in this regard is highly motivated by
their proven capability of promoting tumour initia-
tion and growth (5). We conclude that the close
similarities between CAFs in mouse and human
tumours, as elucidated in the current study, provide
a valuable platform for cross-validation of newly
discovered therapeutic targets and biomarkers
expressed by CAFs.
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